Cargando…
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
PURPOSE: We conducted a retrospective study to compare transarterial chemoembolization (TACE) plus lenvatinib plus programmed death-1 (PD-1) inhibitors with TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with HCC were analyzed from J...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630329/ https://www.ncbi.nlm.nih.gov/pubmed/36338683 http://dx.doi.org/10.3389/fonc.2022.945915 |
_version_ | 1784823578275872768 |
---|---|
author | Guo, Peng Pi, Xingtao Gao, Feng Li, Qiang Li, Duqiang Feng, Wendong Cao, Wendong |
author_facet | Guo, Peng Pi, Xingtao Gao, Feng Li, Qiang Li, Duqiang Feng, Wendong Cao, Wendong |
author_sort | Guo, Peng |
collection | PubMed |
description | PURPOSE: We conducted a retrospective study to compare transarterial chemoembolization (TACE) plus lenvatinib plus programmed death-1 (PD-1) inhibitors with TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with HCC were analyzed from January 2018 to January 2022 in three hospitals. Patients received TACE plus lenvatinib with or without PD-1 inhibitors (TACE+L+PD-1 or TACE+L, respectively). The baseline characteristics of the two groups were compared, and propensity score matching (PSM) was performed. Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) of the two groups were compared. Adverse events in the two groups were analyzed. RESULTS: A total of 166 patients were evaluated (TACE+L+PD-1, n = 75; TACE+L, n = 91). Before PSM, OS was prolonged in the TACE+L+PD-1 group (p = 0.010), but PFS was similar between the two groups (p = 0.18). ORR was higher in the TACE+L+PD-1 group (p = 0.047). After PSM, estimated OS rates at 6, 12, and 24 months were 97.9%, 84.6%, and 74.1%, respectively, in the TACE+L+PD-1 group (n = 48) and 93.1%, 66.1%, and 43.4%, respectively, in the TACE+L group (n = 48). Estimated PFS rates at 3, 6, and 12 months were 81.9%, 61.8%, and 30.9%, respectively, in the TACE+L group and 95.7%, 82.1%, and 68.4%, respectively, in the TACE+L+PD-1 group. OS, PFS, and ORR were improved in the TACE+L+PD-1 group compared to the TACE+L group (p = 0.030; p = 0.027; p = 0.013). The safety of the TACE+L+PD-1 regimen was acceptable. CONCLUSIONS: The addition of PD-1 inhibitors to TACE+L significantly improved clinical outcomes in patients with unresectable HCC. Side effects were manageable. |
format | Online Article Text |
id | pubmed-9630329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96303292022-11-04 Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study Guo, Peng Pi, Xingtao Gao, Feng Li, Qiang Li, Duqiang Feng, Wendong Cao, Wendong Front Oncol Oncology PURPOSE: We conducted a retrospective study to compare transarterial chemoembolization (TACE) plus lenvatinib plus programmed death-1 (PD-1) inhibitors with TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with HCC were analyzed from January 2018 to January 2022 in three hospitals. Patients received TACE plus lenvatinib with or without PD-1 inhibitors (TACE+L+PD-1 or TACE+L, respectively). The baseline characteristics of the two groups were compared, and propensity score matching (PSM) was performed. Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) of the two groups were compared. Adverse events in the two groups were analyzed. RESULTS: A total of 166 patients were evaluated (TACE+L+PD-1, n = 75; TACE+L, n = 91). Before PSM, OS was prolonged in the TACE+L+PD-1 group (p = 0.010), but PFS was similar between the two groups (p = 0.18). ORR was higher in the TACE+L+PD-1 group (p = 0.047). After PSM, estimated OS rates at 6, 12, and 24 months were 97.9%, 84.6%, and 74.1%, respectively, in the TACE+L+PD-1 group (n = 48) and 93.1%, 66.1%, and 43.4%, respectively, in the TACE+L group (n = 48). Estimated PFS rates at 3, 6, and 12 months were 81.9%, 61.8%, and 30.9%, respectively, in the TACE+L group and 95.7%, 82.1%, and 68.4%, respectively, in the TACE+L+PD-1 group. OS, PFS, and ORR were improved in the TACE+L+PD-1 group compared to the TACE+L group (p = 0.030; p = 0.027; p = 0.013). The safety of the TACE+L+PD-1 regimen was acceptable. CONCLUSIONS: The addition of PD-1 inhibitors to TACE+L significantly improved clinical outcomes in patients with unresectable HCC. Side effects were manageable. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9630329/ /pubmed/36338683 http://dx.doi.org/10.3389/fonc.2022.945915 Text en Copyright © 2022 Guo, Pi, Gao, Li, Li, Feng and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Guo, Peng Pi, Xingtao Gao, Feng Li, Qiang Li, Duqiang Feng, Wendong Cao, Wendong Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title | Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title_full | Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title_fullStr | Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title_full_unstemmed | Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title_short | Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study |
title_sort | transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: a propensity score matching study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630329/ https://www.ncbi.nlm.nih.gov/pubmed/36338683 http://dx.doi.org/10.3389/fonc.2022.945915 |
work_keys_str_mv | AT guopeng transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT pixingtao transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT gaofeng transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT liqiang transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT liduqiang transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT fengwendong transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy AT caowendong transarterialchemoembolizationpluslenvatinibwithorwithoutprogrammeddeath1inhibitorsforpatientswithunresectablehepatocellularcarcinomaapropensityscorematchingstudy |